Amylyx Pharmaceuticals

Amylyx Pharmaceuticals, Inc. operates as a biopharmaceutical company, which provides disease-modifying solutions for neurodegenerative diseases. The firm focuses on streamlined clinical development and drug discovery. It specializes in developing a proprietary therapeutic for Amyotrophic Lateral Sclerosis (ALS) and other neurodegenerative diseases that target the neuroinflammation and nerve cell death that characterize these disorders. The company was founded by Joshua Cohen and Justin Klee in 2013 and is headquartered in Cambridge, MA.

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Amylyx Pharmaceuticals excels in Q4 with RELYVRIO launch success

Amylyx Pharmaceuticals demonstrated strong financial performance in Q4 2022, driven by the successful commercial launch of RELYVRIO for ALS treatment.
The company's focus on key priorities for the U.S. launch and commitment to serving ALS patients position it well for future growth and impact.
While facing challenges in meeting analyst expectations and study success criteria, Amylyx Pharmaceuticals remains optimistic about the opportunities ahead in advancing ALS treatment.

Amylyx Pharmaceuticals achieves profitability in Q1, plans global PSP study

Amylyx Pharmaceuticals delivered strong financial performance in Q1, driven by the success of RELYVRIO and plans for AMX0035 in PSP. While facing challenges in profitability expectations and pipeline expansion, the company is well-positioned to capitalize on opportunities for growth and impact.

Amylyx Pharmaceuticals reports robust Q2 performance and strategic growth focus

Amylyx Pharmaceuticals' Q2 2023 Earnings Call highlighted strong financials, patient-centric initiatives, and advancements in R&D programs for neurodegenerative diseases.
Analysts' inquiries underscored the need for clarity on compliance rates, expansion strategies, and study design considerations to address potential challenges.
The company's emphasis on trial design strength, patient support, and market positioning opportunities signals a strategic focus on growth and innovation.

Amylyx Pharmaceuticals reports strong Q3 earnings, eyes growth opportunities

Amylyx Pharmaceuticals had a strong Q3 performance with significant net product revenues and a focus on expanding patient reach. While facing challenges in discontinuations and revenue impact, the company is optimistic about growth opportunities through education and trial results.

Amylyx Pharmaceuticals reports robust earnings, poised for market expansion

Amylyx Pharmaceuticals had a successful year financially, with strong revenue growth and a solid financial position.
The company's focus on expanding market reach, developing innovative biomarkers, and enhancing disease diagnosis underscores their commitment to advancing ALS treatment.
While facing uncertainties with upcoming trial data and regulatory challenges, Amylyx remains optimistic about growth opportunities and R&D advancements.

Amylyx Pharmaceuticals adapts strategy post-PHOENIX trial, eyes regulatory milestones

Amylyx Pharmaceuticals navigated a challenging quarter with a focus on pipeline diversification and strategic planning for multiple neurodegenerative diseases. Despite setbacks in the PHOENIX trial, the company remains resilient and proactive in addressing challenges while seizing opportunities for growth and regulatory progress.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Amylyx Pharmaceuticals, Inc. is a commercial-stage biotechnology company, which engages in the provision of therapies for neurodegenerative diseases and amyotrophic lateral sclerosis (ALS). Its commercial product is Relyvrio, also known as Albrioza in Canada. The company was founded by Joshua Cohen and Justin Klee in 2013 and is headquartered in Cambridge, MA.

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) (“Amylyx” or the “Company”) today announced that Amylyx' management team will host a conference call and webcast tomorrow, Wednesday, July 10, 2024, at 8:00 a.m. ET to discuss the acquisition of avexitide from Eiger BioPharmaceuticals. To access the conference call, please dial +1 (800) 836-8184 (U.S. and Canada) or +1 (646) 357-8785 (international) at least 10 minutes prior to the start time and ask to be joined int.

Amylyx Pharmaceuticals to Host Conference Call to Discuss the Acquisition of Avexitide

Amylyx Pharmaceuticals, Inc.'s relyvrio for ALS was voluntarily delisted in the U.S. and Canada, but has a chance to target this indication with the advancement of AMX0114; IND filing and trial initiation expected in 2024. Full data from the phase 2 HELIOS trial, using AMX0035 to treat patients with Wolfram syndrome, is expected Fall of 2024. Interim analysis from phase 3 ORION study, using AMX0035 to treat patients with progressive supranuclear palsy, expected mid-2025.

Amylyx Pharmaceuticals: Potential To Redeem Itself With Data Readouts And Possible GLP-1 Acquisition

Eiger BioPharmaceuticals, Inc.

Amylyx Pharmaceuticals has agreed to buy the rights to bankrupt drugmaker Eiger BioPharmaceuticals' experimental drug for low blood sugar in a $35.1 million deal, Eiger said in a filing on Friday.

Amylyx to buy bankrupt Eiger's experimental drug to treat low blood sugar

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals to Present at the Goldman Sachs 45th Annual Global Healthcare Conference.

Amylyx Pharmaceuticals to Present at the Goldman Sachs 45th Annual Global Healthcare Conference

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX ) Q1 2024 Results Conference Call May 9, 2024 8:00 AM ET Company Participants Lindsey Allen - Head, IR & Communications Justin Klee - Co-CEO Camille Bedrosian - CMO Jim Frates - CFO Josh Cohen - Co-CEO Conference Call Participants Corinne Jenkins - Goldman Sachs Graig Suvannavejh - Mizuho Operator Good morning. My name is Morgan, and I will be your conference operator today.

Amylyx Pharmaceuticals, Inc. (AMLX) Q1 2024 Earnings Call Transcript

Amylyx Pharmaceuticals, Inc. (AMLX) came out with a quarterly loss of $0.46 per share versus the Zacks Consensus Estimate of $0.24. This compares to earnings of $0.02 per share a year ago.

Amylyx Pharmaceuticals, Inc. (AMLX) Reports Q1 Loss, Lags Revenue Estimates

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today reported financial results for the first quarter ended March 31, 2024. “As an organization deeply committed to ending the suffering caused by neurodegenerative diseases, we took swift action in the first quarter of 2024 to focus our resources on key clinical and preclinical programs and build on the vital foundation we have laid to date as we drive toward our mission. We are focused.

Amylyx Pharmaceuticals Reports First Quarter 2024 Financial Results

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced that Joshua Cohen and Justin Klee, Co-CEOs of Amylyx, and Camille L. Bedrosian, MD, Chief Medical Officer of Amylyx, will participate in the 2024 Bank of America Health Care Conference. The conference is being conducted in-person in Las Vegas, Nevada, and the fireside chat will take place on Wednesday, May 15, 2024, at 8:40 a.m. PT/11:40 a.m. ET. A live webcast of the prese.

Amylyx Pharmaceuticals to Present at the 2024 Bank of America Health Care Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) will report its first quarter 2024 financial results on Thursday, May 9, 2024. Amylyx' senior management team will host a conference call and audio webcast at 8:00 a.m. ET to discuss the financial results and other company updates. To access the conference call, please dial +1 (877)-346-6112 (U.S. & Canada) or +1 (848)-280-6350 (international) at least 10 minutes prior to the start tim.

Amylyx Pharmaceuticals to Report First Quarter 2024 Financial Results on May 9, 2024

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals Announces Interim Data From Ongoing Phase 2 HELIOS Clinical Trial.

Amylyx Pharmaceuticals Announces Interim Data From Ongoing Phase 2 HELIOS Clinical Trial Demonstrating Improvements in Pancreatic Function and Glycemic Control with AMX0035 in People with Wolfram Syndrome

NEW YORK, NY / ACCESSWIRE / April 9, 2024 / If you suffered a loss on your Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/amylyx-lawsuit-submission-form?prid=74968&wire=1 or contact Joseph E. Levi, Esq.

April 9, 2024 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against - AMLX

NEW YORK, NY / ACCESSWIRE / April 9, 2024 / If you suffered a loss on your Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/amylyx-lawsuit-submission-form?prid=74944&wire=1 or contact Joseph E. Levi, Esq.

Investors in Amylyx Pharmaceuticals, Inc. Should Contact Levi & Korsinsky Before April 9, 2024 to Discuss Your Rights - AMLX

NEW YORK, NY / ACCESSWIRE / April 9, 2024 / If you suffered a loss on your Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/amylyx-lawsuit-submission-form?prid=74879&wire=1 or contact Joseph E. Levi, Esq.

Levi & Korsinsky Notifies Shareholders of Amylyx Pharmaceuticals, Inc.(AMLX) of a Class Action Lawsuit and an Upcoming Deadline

LOS ANGELES, CA / ACCESSWIRE / April 9, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Amylyx Pharmaceuticals, Inc. ("Amylyx" or "the Company") (NASDAQ:AMLX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between November 11, 2022 and November 8, 2023, inclusive (the "Class Period"), are encouraged to contact the firm before April 9, 2024.

FINAL DEADLINE TODAY: The Schall Law Firm Encourages Investors in Amylyx Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm

NEW YORK , April 9, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX). Shareholders who purchased shares of AMLX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.

The Gross Law Firm Notifies Amylyx Pharmaceuticals, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - AMLX

NEW YORK, NY / ACCESSWIRE / April 9, 2024 / If you suffered a loss on your Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/amylyx-lawsuit-submission-form?prid=74857&wire=1 or contact Joseph E. Levi, Esq.

Lost Money on Amylyx Pharmaceuticals, Inc. (AMLX)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky

NEW YORK, NY / ACCESSWIRE / April 8, 2024 / If you suffered a loss on your Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/amylyx-lawsuit-submission-form?prid=74827&wire=1 or contact Joseph E. Levi, Esq.

Investors in Amylyx Pharmaceuticals, Inc. Should Contact Levi & Korsinsky Before April 9, 2024 to Discuss Your Rights – AMLX

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz reminds investors of the upcoming April 9, 2024 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who acquired Amylyx Pharmaceuticals, Inc. (“Amylyx” or the “Company”) (NASDAQ: AMLX) securities between November 11, 2022 and November 8, 2023, inclusive (the “Class Period”). If you are a shareholder who suffered a loss, click here to participate. On November 9, 2023, Amylyx released its third qu.

The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Amylyx Pharmaceuticals, Inc. (AMLX)

NEW YORK, NY / ACCESSWIRE / April 8, 2024 / If you suffered a loss on your Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/amylyx-lawsuit-submission-form?prid=74747&wire=1 or contact Joseph E. Levi, Esq.

Amylyx Pharmaceuticals, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - AMLX

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced the Company will host a virtual webcast with management and Fumihiko Urano, MD, PhD, Principal Investigator of the HELIOS clinical trial and the Samuel E. Schechter Professor of Medicine in the Division of Endocrinology, Metabolism & Lipid Research at Washington University School of Medicine in St. Louis to discuss interim data from HELIOS, a Phase 2 trial of AMX0035 fo.

Amylyx Pharmaceuticals to Host Virtual Webcast to Discuss Interim Data from Phase 2 HELIOS Study of AMX0035 in Wolfram Syndrome on April 10, 2024

LOS ANGELES, CA / ACCESSWIRE / April 8, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Amylyx Pharmaceuticals, Inc. ("Amylyx" or "the Company") (NASDAQ:AMLX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between November 11, 2022 and November 8, 2023, inclusive (the "Class Period"), are encouraged to contact the firm before April 9, 2024.

FINAL DEADLINE TOMORROW: The Schall Law Firm Encourages Investors in Amylyx Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm

NEW YORK , April 8, 2024 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Amylyx Pharmaceuticals, Inc. ("Amylyx" or the "Company") (NASDAQ: AMLX) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Amylyx investors who were adversely affected by alleged securities fraud between November 11, 2022 and November 8, 2023.

Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Amylyx Pharmaceuticals, Inc.(AMLX) Shareholders

NEW YORK, NY / ACCESSWIRE / April 8, 2024 / If you suffered a loss on your Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/amylyx-lawsuit-submission-form?prid=74654&wire=1 or contact Joseph E. Levi, Esq.

Amylyx Pharmaceuticals, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before April 9, 2024 to Discuss Your Rights - AMLX

NEW YORK, NY / ACCESSWIRE / April 7, 2024 / If you suffered a loss on your Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/amylyx-lawsuit-submission-form?prid=74636&wire=1 or contact Joseph E. Levi, Esq.

AMLX LAWSUIT ALERT: Levi & Korsinsky Notifies Amylyx Pharmaceuticals, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline

NEW YORK, NY / ACCESSWIRE / April 7, 2024 / If you suffered a loss on your Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/amylyx-lawsuit-submission-form?prid=74613&wire=1 or contact Joseph E. Levi, Esq.

News for Amylyx Pharmaceuticals Stock (AMLX)